Serological Study of the Exposure of Personnel to COVID-19

Sars-CoV2 Clinical Trial

— SEROPHUGAC  

Official title:

Serological Study of the Exposure of Personnel to Sars-cov-2 in an Urban Hospital Two Months After Managing an Influx of COVID Patients 19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04422977
• Other study ID #: SEROPHUGAC
• Status: Completed
• Phase: N/A
• Start date: June 8, 2020
• Est. completion date: July 10, 2020

Study information

• Verified date: April 2024
• Source: Centre Hospitalier Saint Joseph Saint Luc de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A seroconversion test for SARS-Cov-2 will be offered to all the employees of a care institution, which has treated 240 patients hospitalized for COVID disease between 28/02 and 30/04/2020. The seroconversion test will be with a questionnaire to determine:

• whether the subject has shown signs of infection in the last 3 recent months

• if the subject has been in contact with COVID-diagnosed subjects (RT-PCR diagnosis or scanner) outside of the activity or within the professional activity (patient or colleague)

• Working conditions during the period

• The level of knowledge and respect of the barrier measures practices.

• Respect for distance during meals professional. Overall seroprevalence and stratified seroprevalence by care and administrative areas will be determined.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 957
• Est. completion date: July 10, 2020
• Est. primary completion date: July 10, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Subject who worked at Saint Joseph Saint Luke's Hospital during the epidemic wave (male or female).

• Free and informed consent

• Social security affiliation

Exclusion Criteria:

• Subject refusal

• Subject on leave during the entire period

Related Conditions & MeSH terms

• Sars-CoV2

Intervention

Diagnostic Test:
• Sars-Cov-2 serology
Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff

Locations

Country	Name	City	State
France	Centre Hospitalier St Joseph St Luc	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Saint Joseph Saint Luc de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff with a seroconversion test for SARS-Cov-2	Measurement of overall seroprevalence of SARS-Cov-2 in an hospital staff	1 month